Enzymatic and non-enzymatic oxygenations of unsaturated fatty acids yield a broad family of autocrine and paracrine cell signaling mediators. Soon after nitric oxide (•NO) was described as a mediator of vascular relaxation, it was appreciated that this lipophilic free radical species strongly influences fatty acid oxygenation at multiple levels. For example, •NO terminates peroxyl radical-induced chain propagation reactions of lipid peroxidation at rate constants >103 faster than tocopherols (1, 2). Also, the gene expression and catalytic activity of enzymes responsible for prostaglandin, thromboxane, and leukotriene biosynthesis are regulated by •NO (3–5). Another convergence of lipid and •NO signaling is manifested in the form of nitrated unsaturated fatty acids. Fatty acid nitration is induced by •NO-derived species reacting via multiple mechanisms that share a proclivity for the homolytic addition of nitrogen dioxide (•NO2) to the double bond, yielding an array of regio- and stereoisomers (6). NO2-FAs3 display both cGMP-independent and receptor-dependent signaling actions as well as robust electrophilic reactivity, facilitating reversible adduction by nucleophilic targets (e.g. protein Cys and His residues) (7, 8). This reactivity in turn supports the post-translational modification of protein distribution and function. Both NO2-FAs and their protein or GSH adduction products are detected clinically in healthy individuals, become elevated postprandially, and are formed by oxidative inflammatory reactions (8–12). Current data indicate that NO2-FAs signal via predominantly •NO-independent mechanisms, acting via electrophilic and receptor-mediated reactions to exert adaptive and anti-inflammatory cell responses.
Mechanisms of Fatty Acid Nitration
The biochemistry of fatty acid nitration stems from the reactions of
•NO, •NO-derived oxides of nitrogen
(e.g. nitrogen dioxide (•NO2) and
peroxynitrite (ONOO–)), and oxygen-derived inflammatory
mediators (e.g. superoxide
(
),
hydrogen peroxide (H2O2), and lipid peroxyl radicals
(LOO•)). Multiple mechanisms induce biomolecule nitration,
with this redundancy supporting the concept that nitration reactions transduce
•NO signaling and tissue inflammatory responses. The formation
of secondary •NO-derived species and the subsequent reactions
that mediate biomolecule nitration are dictated by •NO
concentration; oxygen tension; site of generation; local concentrations of
targets, catalysts, and scavengers; and partitioning between hydrophobic and
hydrophilic compartments (13).
These factors also reflect cell metabolic and inflammatory status and
ultimately govern relative extents of target molecule oxidation, nitrosation,
and nitration.
Peroxynitrite-mediated—Appreciation of the
•NO- and
-dependent
formation of the oxidizing and nitrating species ONOO– shed
new light on the myriad of downstream effects this reaction has on redox
signaling (14,
15). In addition to reaction
with thiols, ONOO– reaction with carbon dioxide predominates
in tissues, yielding
. In an
inflammatory milieu, both protonated ONOO– (ONOOH) and
yield
•NO2 along with •OH and
as products that
can support biomolecule nitration reactions
(16).
Peroxidase-catalyzed and Fenton-induced Oxidation of
to
•NO2—Peroxidases catalyze the reduction
of H2O2 and organic peroxides and in turn catalyze the
oxidation of organic compounds, inorganic anions, and halides. Upon oxidation
by hydroperoxides, the oxidation of
to •NO2 is mediated by peroxidases,
microperoxidases, hemeproteins, and transition metals (e.g. Fe(II)
acting via iron-catalyzed Fenton chemistry)
(17–19).
Protonation of
—Nitrite
(
), the principal physiologic
metabolite of •NO, can be protonated to nitrous acid
(HNO2, pKa 3.4) in acidic tissue environments
such as the gastric compartment, phagolysosomes. and endosomes. The further
reactions of HNO2 in an aqueous milieu then yield a spectrum of
nitrating and nitrosating species that induce biomolecule nitration via either
free radical or ionic addition reactions.
Acidic nitration can be a confounding event in NO2-FA analysis
and quantification because of the low pH and adventitious
that can be experienced upon sample
extraction, hydrolysis, derivatization, and chromatographic separations.
Aerobic Reactions of •NO—Because of a small molecular radius and uncharged nature, •NO is lipophilic and can concentrate up to 20-fold and more readily react with the molecular O2 that also preferentially partitions into a hydrophobic milieu (20). This molecular “lens” effect induced by •NO and O2 concentration in hydrophobic compartments can accelerate •NO oxidation by 2–3 orders of magnitude. This lens effect thus promotes the formation of secondary •NO-derived species from O2 (k = 2 × 106 m–2 s–1), including •NO2 (Fig. 1) (21).
FIGURE 1.

Mechanisms of fatty acid nitration and oxidation by nitric oxide-derived species.
The chemistry of unsaturated fatty acid nitration and detection of reaction products in vivo is dictated not only by the intrinsic reactivity of the double bonds, but also by the biological microenvironment of target molecules that includes factors such as (a) relative fluxes of instigating oxidizing and nitrating species; (b) adventitious catalysts, antioxidants, and nucleophiles; and (c) local rates of fatty acid esterification, de-esterification, and β-oxidation reactions. Unsaturated fatty acids such as linoleic acid, oleic acid, and their congeners represent important targets because of both their abundance and an availability of double bonds susceptible to •NO2 attack via both homolytic and heterolytic (ionic) reactions. In addition, the bisallylic methylene centers represent another potential reactive site of polyunsaturated fatty acids because of their susceptibility to hydrogen atom abstraction.
Nitrated unsaturated fatty acids identified in vivo to date belong
to two main groups, nitroalkene and nitrohydroxy (nitroalcohol) derivatives,
with preliminary observations also suggesting fully saturated and allylic
NO2-FA derivatives. Chemically, E-nitroalkene derivatives
of unsaturated fatty acids and their esters are formed in vitro under
a variety of conditions. They represent relatively abundant and less polar
components of mixtures obtained by reaction of fatty acids or esters with (i)
•NO in air-equilibrated cyclohexane
(22,
23) or (ii) acidic
in a biphasic cyclohexane system
(24,
25). Fatty acid nitroalkene
formation is invariably accompanied by other nitration products, including,
besides the Z-isomers, allylic nitro, nitronitrate, and dinitro
derivatives as well as hydroxynitro compounds (see supplemental material for
NMR, IR, and MS characteristics of many of these species)
(24,
26). Oxygen is essential for
fatty acid reactions with •NO, consistent with the chemical
inertness of •NO toward alkenes. In aerobic
•NO-promoted reactions, the chemical course and product
composition change considerably with •NO concentration and
solvent polarity: nitrated species are the main products in cyclohexane,
whereas peroxidation products predominate in neutral aqueous phosphate buffer
(22,
23).
In the first step of fatty acid nitration, •NO2 adds to alkene double bonds via a fast and reversible process to initially form β-nitroalkyl radicals. In hydrophobic environments, where the solubility of •NO and related nitrogen oxides is relatively high, these radicals can evolve to give nitrated derivatives. However, in an aqueous milieu, where the solubility of •NO and related species is about an order of magnitude lower, trapping of the β-nitroalkyl radical is less efficient. The radical intermediates then revert, and the slow but irreversible allylic hydrogen atom abstraction by •NO2 (for •NO2, kadd/kabs ∼ 103–106) eventually prevails, initiating chain peroxidation reactions (27). Under conditions in which O2 tension is low (e.g. ischemia and anoxia), the balance between peroxyl radical formation and coupling with •NO2 shifts toward nitration reactions. With regard to stereochemistry of the products, the nitro group preferentially constrains the double bond of nitroalkene derivatives in the cis (E)-configuration, with only a minor proportion present as trans-isomers. This implies that the original double bond configuration of the parent fatty acid is retained in nitrated derivatives. The two primary reaction pathways of polyunsaturated fatty acids with the proximal nitrating species •NO2 are outlined in Fig. 1. Chemical evidence indicates that nitration reactions can also occur in the course of lipid peroxidation, modifying conjugated diene intermediates that are generated by enzymatic and non-enzymatic peroxidation of linoleic acid. Carbon chain breakdown and rearrangements induced by HNO2 and ONOO–, respectively, are also possible events leading to secondary fatty acid nitration products (28).
Chemical Reactivities of Nitro-fatty Acids
Analysis of synthetic nitroalkene derivatives of oleic, linoleic, and arachidonic acid reveals that these species possess unique chemical reactivities that support pluripotent cell signaling events. NO2-FAs act via both receptor-dependent and -independent mechanisms that are subject to regulation by the relative distribution of NO2-FAs in hydrophobic and aqueous microenvironments (Fig. 2). At present, there is not strong support for a mitigating role by NO2-FA-derived •NO production.
FIGURE 2.
Biological trafficking and actions of NO2-FA derivatives. Nitroalkenes are stable in free and/or esterified form in hydrophobic micellar, lipoprotein, or membrane environments and can serve as a reserve of NO2-FAs in free and/or esterified form. Once access to an aqueous milieu is gained, nitroalkenes can decay or possibly be metabolized to release nitric oxide (•NO), bind and activate PPARs, or elicit multiple biological responses as a consequence of electrophilic reactivity.
Electrophilic Reaction with Water—The electrophilicity of fatty acid nitroalkene derivatives is central to their subsequent reactions, e.g. Michael conjugate addition with the low amounts of hydroxide anion always present in aqueous solution at physiologic pH. An equilibrium between nitroalkene derivatives and their corresponding vicinal nitrohydroxy fatty acids is indicated by nitrohydroxy fatty acid derivatives in cardiac tissue, blood, and urine (6, 12, 29). The presence of the highly polar hydroxyl group in nitrohydroxy fatty acid derivatives results in these products behaving more like saturated fatty acids.
Aqueous Decay and •NO Release—A mechanism accounting for •NO release by nitroalkenes comes from a reaction of organic nitro derivatives, the Nef reaction. Support for this reaction comes from HPLC-MS detection of expected Nef reaction products, a requirement for an aqueous milieu, the pH dependence of the reaction, and the direct detection of •NO release (30). Under neutral aqueous conditions, nitroalkene equilibrium with vicinal nitrohydroxy derivatives facilitates formation of the nitronate anion (R2-C(–)-NO2). Following concerted protonation and deprotonation events, the resulting nitroso intermediate provides a pathway that yields •NO via a reaction facilitated by reductants such as ascorbate (29). This nitroso intermediate has a weak C–N bond that yields •NO and a carbon-centered radical product stabilized by conjugation with both the alkene and the OH group. The carbon-centered radical can be reduced by various cellular reductive mechanisms to yield the conjugated ketone derivative detected as the final product by HPLC-MS (30). An alternative mechanism for NO release from nitroalkenes has been proposed, involving nitroalkene isomerization to a nitrite ester followed by N–O bond homolysis and/or one-electron reduction to form the corresponding functional enol group and nitric oxide (29, 31). The direct release of •NO from synthetic vicinal nitrohydroxylinoleic and nitrohydroxyarachidonic acid precursors, analogous to those detected in human plasma and urine and bovine cardiac lipid extracts, has also been proposed based on the observation that this species induces vasorelaxation of rat aortic rings (12, 29). Present results indicate that synthetic hydroxy derivatives of fatty acid nitroalkenes are not direct precursors to •NO release, but rather require equilibrium between nitrohydroxy and nitroalkene derivatives. It is important to note that the hydrophobic stabilization of fatty acid nitroalkenes can render pathways leading to •NO release of little or no biological significance.
Electrophilic Adduction of Protein Thiol and Histidine Residues—The post-translational modification of proteins by electrophilic oxidative reaction products is typically viewed as an index of toxicity. Electrophilic adduction reactions are now also viewed to instigate adaptive responses that are mediated by the nitroalkylation of critical thiols and other nucleophilic moieties of transcription factors, ion channels, and cell signaling proteins (32). Nitroalkenes react with the thiolate anion of GSH and Cys via Michael addition at robust bimolecular rate constants significantly exceeding most fatty acid-derived electrophiles, displaying second order rate constants of up to 355 m–1 s–1 at pH 7.4 and 37 °C (7). These are orders of magnitude greater than for GSH reaction with H2O2 and electrophilic lipids such as 8-isoprostaglandin A2 and 15-deoxy-Δ12,14-prostaglandin J2. The electrophilic adduction of proteins by NO2-FAs gains additional significance in the context of cell signaling, as this reaction is reversible, a necessary trait for signaling mediators. Protein adduction by NO2-FAs is detected clinically, thus representing a metabolic and redox-sensitive mechanism for regulating protein distribution and function.
Hydrophobic Stabilization—Fatty acid nitroalkene derivatives are highly stable in polyethylene glycols, alcohols, and other less polar organic solvents. When partitioned in non-ionic detergent micelles or phosphatidylcholine/cholesterol liposomes, the parent nitroalkene is stabilized, thus inhibiting (a) decomposition via the Nef reaction and •NO release and (b) electrophilic reaction with thiols (7, 30). This suggests that upon partitioning or esterification to complex lipids in cell membranes and lipoproteins, NO2-FAs exist in a stabilized form that can be mobilized for downstream cell signaling actions upon activation of esterases and A2-type phospholipases.
Signaling Actions of Nitro-fatty Acids
cGMP-dependent Vessel Relaxation—Diverse
•NO-derived and •NO-generating molecules
regulate vascular tone. Current evidence reveals endogenously produced
and RSNO derivatives as metabolic
“reserves” for •NO- and downstream cGMP-dependent
signaling (33).
NO2-FAs also induce •NO-dependent vasorelaxation
with an IC50 of 0.1–1 μm when LNO2
is added to preconstricted rat aortic vessel rings
(29,
34). Nitrohydroxy derivatives
of arachidonic acid have also been suggested to induce vasorelaxation
(12). In an aqueous milieu,
nitrohydroxy derivatives of fatty acids will be in equilibrium with their
dehydration product, the nitroalkene, so the immediate precursor of
•NO is uncertain, and the equilibrium constants for
nitrohydroxy fatty acid dehydration remain to be defined
(30). Although
NO2-FAs release •NO in aqueous media following
Nef-like acid-base chemistry
(12,
29,
30), this reaction is
inhibited by intercalation in micelles and liposomes
(30). This apparent
contradiction with vessel relaxation studies, where •NO
intermediacy is implicated by guanylate cyclase inhibitors abolishing vessel
responses to NO2-FAs
(34), has not been resolved.
Possibly, •NO generation by NO2-FAs is
enzymatically catalyzed or the result of NO2-FA activation of a
signaling pathway dependent on •NO. In summary,
nitroalkene-dependent •NO release and vessel relaxation may be
an anomaly, as the signaling actions described below are not the consequence
of •NO-dependent, cGMP-mediated reactions.
Inhibition of Inflammatory Cell Function—NO2-FA
derivatives inhibit neutrophil (PMN) and platelet function via
non-cGMP-dependent mechanisms
(35,
36). In activated PMNs,
LNO2 inhibited
.
production, azurophilic degranulation, calcium mobilization, and CD11b
expression via •NO-independent mechanisms. Exposure of both
PMNs and platelets to LNO2 increased cAMP levels
(37). In platelets,
LNO2 inhibited thrombin-induced aggregation by increasing platelet
cAMP levels, with inhibitors of adenylate cyclase restoring thrombin-induced
aggregation to platelets pretreated with LNO2
(36). Growing evidence
supports that LNO2 induces adenylate cyclase activity, which is in
part mediated by the cAMP-dependent phosphorylation of Ser159 in
vasodilator-stimulated phosphoprotein, causing a decrease in cAMP hydrolysis
in PMNs and macrophages. Activated macrophage nitric-oxide synthase-2
expression is down-regulated by nitroarachidonic acid, an event that also
inhibits subsequent macrophage inflammatory responses
(38). The transendothelial
migration of monocytes is largely dependent on a class of adhesion molecules,
including VCAM-1, E-selectin, and P-selectin. VCAM-1 is a central mediator of
the selective recruitment of monocytes and lymphocytes to atherosclerotic
lesions (39). In this regard,
NO2-FAs suppress the expression of VCAM-1, resulting in impaired
monocyte rolling and adhesion and inhibition of monocyte infiltration
(40). Expanding evidence
supports that NO2-FAs abrogate the activation of multiple
inflammatory cell types via •NO-independent mechanisms and
encourages further study of operative signaling mechanisms.
HO-1 Expression—HO-1 plays a central role in inflammatory signaling, mediating protective responses during inflammation. HO-1 catalyzes the degradation of heme to biliverdin, iron, and CO, the latter of which is isoelectronic with •NO and recently shown to mediate diverse anti-inflammatory, anti-apoptotic, and vasodilatory adaptive signaling actions (41). During inflammation, HO-1 gene expression is up-regulated, with induction typically occurring at the transcriptional level. HO-1 expression is potently induced by LNO2 in human aortic endothelial cells compared with other established stimuli, including oxidized fatty acids and hemin. This induction is not mediated by •NO, NF-κB, or PPARγ (42). Current data support that up-regulation of human HO-1 expression by NO2-FAs requires synergy between the cAMP-response element and AP-1 sequences in the –4.5-kb HO-1 promoter region (43).
Inhibition of NF-κB—The enzymatic and chemical oxidation of fatty acids plays a central role in regulating inflammation. Prostaglandins, thromboxanes, isoprostanes, and leukotrienes mediate the propagation and resolution of inflammation via G-protein-coupled and nuclear receptor activation and in some cases by post-translational protein modification (44, 45). In addition, electrophilic species contribute to the transcriptional regulation of inflammation via post-translational modification of NF-κB (46). NF-κB functions as a hetero- or homodimer of five different subunits (p50, p52, p65, p100, and p105). The dimer between p50 and p65 in particular promotes expression of genes involved with cell survival and the progression of inflammation. Biological electrophiles such as NO2-FAs, 15-deoxy-Δ12,14-prostaglandin J2, and plant-derived sesquiterpene lactones suppress NF-κB transactivation, thus modulating inflammatory signaling. The most responsive sites of electrophile reaction appear to be the alkylation or inhibition of IκB kinase and inhibition of p65 DNA binding. Once activated, IκB kinase phosphorylates the inhibitory IκBα subunit, routing it to degradation. These events are followed by p50/p65 heterodimer nuclear translocation and gene transcription initiation. In particular, NO2-FAs exert a potent inhibitory effect on inflammatory signaling by alkylating the p65 subunit and rendering it unable to bind to the promoter region of inflammatory-related genes. This in turn inhibits tumor necrosis factor-α and lipopolysaccharide-induced secretion of pro-inflammatory cytokines in macrophages and endothelial cells (40).
PPAR Activation—The regulation of nuclear lipid receptor-dependent gene expression by fatty acid derivatives underscores the crucial signaling roles that lipids serve beyond their originally appreciated actions as energy-conserving molecules. For example, oxidized and nitrated fatty acids regulate metabolism and inflammation by activating PPARs (6, 47, 48). Concordant with this concept, elevated NO2-FA levels occur in postprandial and hyperlipidemic human plasma, suggesting an involvement in metabolic homeostasis (10). Three different isoforms of PPAR (α, β, and γ) display unique tissue expression profiles and contribute to the regulation of fat metabolism, adipogenesis, glucose homeostasis, and inflammatory responses. Upon binding of lipophilic ligands, PPARγ forms a heterodimer with the retinoid X receptor, binds to PPAR-response elements, and regulates target gene transcription. PPARγ is broadly expressed by a variety of cells, including monocytes, macrophages, endothelial cells, vascular smooth muscle cells, and adipocytes. Luciferase-based transactivation analysis shows that NO2-FAs are robust agonists of PPARγ and, to a lesser extent, PPARα and PPARδ. The affinity of NO2-FAs as ligands for PPARγ rivals the TZD rosiglitazone, an antidiabetic drug (Ki for [3H]rosiglitazone displacement = 133 nm for LNO2 versus 53 nm for rosiglitazone) (6, 48). As for TZDs, NO2-FAs induce increased adipocyte glucose uptake (6, 48). Despite transactivation assay potencies, receptor affinities, and effects on glucose uptake that are commensurate with TZDs, NO2-FAs display a reduced capacity to induce adipogenesis compared with TZDs such as rosiglitazone. Rosiglitazone induces more extensive preadipocyte differentiation and adipocyte triglyceride accumulation compared with NO2-FAs, suggesting unique properties of NO2-FAs as PPAR ligands in the context of co-regulator protein interactions or other aspects of PPAR activation (6, 48).
Keap1/Nrf2 Activation—Covalent post-translational protein adduction by electrophilic fatty acid derivatives alters the structure, trafficking, and catalytic activity of proteins such as cathepsin B (49), insulin (50), glyceraldehyde-3-phosphate dehydrogenase (51, 52), and Keap1 (53). In particular, thiol adduction of Keap1 induces phase II gene expression, a mechanism that protects against pathogens, metabolic stress, and irreversible inflammatory injury. Phase II protein expression is regulated by the antioxidant-response element, a cis-acting DNA regulatory element also referred to as the electrophile-response element. The thiol oxidation-mediated mechanism that controls antioxidant-response element-dependent electrophile responses consists of the pivotal Nrf2 (nuclear factor erythroid 2-related factor 2) and the electrophile-reactive, cysteine-rich cytoplasmic suppressor protein Keap1 (Kelch-like ECH-associating protein 1). Keap1/Nrf2-mediated signaling is protective against toxicant exposure and acts through multiple kinase signaling pathways (54). The electrophilic reactivity of NO2-FAs inhibits vascular smooth muscle cell proliferation via PPAR- and •NO-independent, Keap1/Nrf2-dependent signaling (55). Current data support that NO2-FAs post-translationally modify critical thiols in Keap1 to ultimately facilitate Nrf2 translocation to the nucleus and transactivation of the expression of cytoprotective and anti-proliferative genes.
Summary
The endogenous generation of NO2-FAs and other electrophilic lipids in turn activates networks of lipid receptors, transcription factors, and signaling pathways that sense changes in tissue levels of oxidative inflammatory mediators. These stimulus-response mechanisms confer the ability to sense and rapidly adapt to changes in metabolic, redox, and inflammatory status via an immediate impact on protein function and by altering patterns of gene expression. The formation and signaling actions of nitrated unsaturated fatty acids thus expand the array of molecular targets regulated by •NO and lipid signaling mediators and represent a redox-sensitive signaling mechanism that responds adaptively to multiple facets of cell metabolism.
Supplementary Material
This work was supported, in whole or in part, by National Institutes of Health Grants R01 HL58115 and R01 HL64937. This work was also supported by the American Diabetes Association, the American Heart Association, and the Ministry of Health (Rome). This is the second article of seven in the Oxidized Lipids Minireview Series. This minireview will be reprinted in the 2008 Minireview Compendium, which will be available in January, 2009.
The on-line version of this article (available at http://www.jbc.org) contains supplemental Figs. 1–3, Tables 1–7, and additional references.
Footnotes
The abbreviations used are: NO2-FA, nitro-fatty acid; MS, mass spectrometry; HPLC, high pressure liquid chromatography; RSNO, S-nitrosothiol; LNO2, 9,10,12- and 13-nitro-9,12-cis-octadecadienoic acid (nitrated linoleic acid); PMN, polymorphonuclear leukocyte; VCAM-1, vascular cell adhesion molecule-1; heme oxygenase-1, HO-1; PPAR, peroxisome proliferator-activated receptor; TZD, thiazolidinedione.
References
- 1.Rubbo, H., Radi, R., Anselmi, D., Kirk, M., Barnes, S., Butler, J., Eiserich, J. P., and Freeman, B. A. (2000) J. Biol. Chem. 275 10812–10818 [DOI] [PubMed] [Google Scholar]
- 2.O'Donnell, V. B., Chumley, P. H., Hogg, N., Bloodsworth, A., Darley-Usmar, V. M., and Freeman, B. A. (1997) Biochemistry 36 15216–15223 [DOI] [PubMed] [Google Scholar]
- 3.Mollace, V., Muscoli, C., Masini, E., Cuzzocrea, S., and Salvemini, D. (2005) Pharmacol. Rev. 57 217–252 [DOI] [PubMed] [Google Scholar]
- 4.O'Donnell, V. B., Coles, B., Lewis, M. J., Crews, B. C., Marnett, L. J., and Freeman, B. A. (2000) J. Biol. Chem. 275 38239–38244 [DOI] [PubMed] [Google Scholar]
- 5.O'Donnell, V. B., Taylor, K. B., Parthasarathy, S., Kuhn, H., Koesling, D., Friebe, A., Bloodsworth, A., Darley-Usmar, V. M., and Freeman, B. A. (1999) J. Biol. Chem. 274 20083–20091 [DOI] [PubMed] [Google Scholar]
- 6.Baker, P. R. S., Lin, Y., Schopfer, F. J., Woodcock, S. R., Groeger, A. L., Batthyany, C., Sweeney, S., Long, M. H., Iles, K. E., Baker, L. M. S., Branchaud, B. P., Chen, Y. E., and Freeman, B. A. (2005) J. Biol. Chem. 280 42464–42475 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Baker, L. M. S, Baker, P. R. S., Golin-Bisello, F., Schopfer, F. J., Fink, M., Woodcock, S. R., Branchaud, B. P., Radi, R., and Freeman, B. A. (2007) J. Biol. Chem. 282 31085–31093 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Batthyany, C., Schopfer, F. J., Baker, P. R. S., Duran, R., Baker, L. M. S., Huang, Y., Cervenansky, C., Branchaud, B. P., and Freeman, B. A. (2006) J. Biol. Chem. 281 20450–20463 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Lima, E. S., Di Mascio, P., Rubbo, H., and Abdalla, D. S. (2002) Biochemistry 41 10717–10722 [DOI] [PubMed] [Google Scholar]
- 10.Rubbo, H., Radi, R., Trujillo, M., Telleri, R., Kalyanaraman, B., Barnes, S., Kirk, M., and Freeman, B. A. (1994) J. Biol. Chem. 269 26066–26075 [PubMed] [Google Scholar]
- 11.Alexander, R. L., Bates, D. J., Wright, M. W., King, S. B., and Morrow, C. S. (2006) Biochemistry 45 7889–7896 [DOI] [PubMed] [Google Scholar]
- 12.Balazy, M., Iesaki, T., Park, J. L., Jiang, H., Kaminski, P. M., and Wolin, M. S. (2001) J. Pharmacol. Exp. Ther. 299 611–619 [PubMed] [Google Scholar]
- 13.Schopfer, F. J., Baker, P. R. S, and Freeman, B. A. (2003) Trends Biochem. Sci. 28 646–654 [DOI] [PubMed] [Google Scholar]
- 14.Beckman, J. S., Beckman, T. W., Chen, J., Marshall, P. A., and Freeman, B. A. (1990) Proc. Natl. Acad. Sci. U. S. A. 87 1620–1624 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Radi, R., Beckman, J. S., Bush, K. M., and Freeman, B. A. (1991) J. Biol. Chem. 266 4244–4250 [PubMed] [Google Scholar]
- 16.Radi, R., Denicola, A., and Freeman, B. A. (1999) Methods Enzymol. 301 353–367 [DOI] [PubMed] [Google Scholar]
- 17.Brennan, M. L., Wu, W., Fu, X., Shen, Z., Song, W., Frost, H., Vadseth, C., Narine, L., Lenkiewicz, E., Borchers, M. T., Lusis, A. J., Lee, J. J., Lee, N. A., Abu-Soud, H. M., Ischiropoulos, H., and Hazen, S. L. (2002) J. Biol. Chem. 277 17415–17427 [DOI] [PubMed] [Google Scholar]
- 18.Eiserich, J. P., Hristova, M., Cross, C. E., Jones, A. D., Freeman, B. A., Halliwell, B., and Van der Vliet, A. (1998) Nature 391 393–397 [DOI] [PubMed] [Google Scholar]
- 19.Castro, L., Eiserich, J. P., Sweeney, S., Radi, R., and Freeman, B. A. (2004) Arch. Biochem. Biophys. 421 99–107 [DOI] [PubMed] [Google Scholar]
- 20.Moller, M., Botti, H., Batthyany, C., Rubbo, H., Radi, R., and Denicola, A. (2005) J. Biol. Chem. 280 8850–8854 [DOI] [PubMed] [Google Scholar]
- 21.Lancaster, J. R., Jr. (2006) Chem. Res. Toxicol. 19 1160–1174 [DOI] [PubMed] [Google Scholar]
- 22.d'Ischia, M., Rega, N., and Barone, V. (1999) Tetrahedron 55 9297–9308 [Google Scholar]
- 23.d'Ischia, M. (1996) Tetrahedron Lett. 37 5773–5774 [Google Scholar]
- 24.Napolitano, A., Camera, E., Picardo, M., and d'Ischia, M. (2000) J. Org. Chem. 65 4853–4860 [DOI] [PubMed] [Google Scholar]
- 25.Napolitano, A., Crescenzi, O., Camera, E., Giudicianni, I., Picardo, M., and d'Ischia, M. (2004) Tetrahedron 58 5061–5067 [Google Scholar]
- 26.Napolitano, A., Panzella, L., Savarese, M., Sacchi, R., Giudicianni, I., Paolillo, L., and d'Ischia, M. (2004) Chem. Res. Toxicol. 17 1329–1337 [DOI] [PubMed] [Google Scholar]
- 27.Pryor, W. A., Lightsey, J. W., and Church, D. F. (1982) J. Am. Chem. Soc. 104 6685–6692 [Google Scholar]
- 28.Napolitano, A., and d'Ischia, M. (2002) J. Org. Chem. 67 803–810 [DOI] [PubMed] [Google Scholar]
- 29.Lima, E. S., Bonini, M. G., Augusto, O., Barbeiro, H. V., Souza, H. P., and Abdalla, D. S. (2005) Free Radic. Biol. Med. 39 532–539 [DOI] [PubMed] [Google Scholar]
- 30.Schopfer, F. J., Baker, P. R. S., Giles, G., Chumley, P. H., Batthyany, C., Crawford, J., Patel, R. P., Hogg, N., Branchaud, B. P., Lancaster, J. R., Jr., and Freeman, B. A. (2005) J. Biol. Chem. 280 19289–19297 [DOI] [PubMed] [Google Scholar]
- 31.Gorczynski, M. J., Huang, J., and King, S. B. (2006) Org. Lett. 8 2305–2308 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Kobayashi, A., Kang, M. I., Watai, Y., Tong, K. I., Shibata, T., Uchida, K., and Yamamoto, M. (2006) Mol. Cell. Biol. 26 221–229 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Gladwin, M. T., Schechter, A. N., Kim-Shapiro, D. B., Patel, R. P., Hogg, N., Shiva, S., Cannon, R. O., III, Kelm, M., Wink, D. A., Espey, M. G., Oldfield, E. H., Pluta, R. M., Freeman, B. A., Lancaster, J. R., Jr., Feelisch, M., and Lundberg, J. O. (2005) Nat. Chem. Biol. 1 308–314 [DOI] [PubMed] [Google Scholar]
- 34.Lim, D. G., Sweeney, S., Bloodsworth, A., White, C. R., Chumley, P. H., Krishna, N. R., Schopfer, F., O'Donnell, V. B., Eiserich, J. P., and Freeman, B. A. (2002) Proc. Natl. Acad. Sci. U. S. A. 99 15941–15946 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Coles, B., Bloodsworth, A., Clark, S. R., Lewis, M. J., Cross, A. R., Freeman, B. A., and O'Donnell, V. B. (2002) Circ. Res. 91 375–381 [DOI] [PubMed] [Google Scholar]
- 36.Coles, B., Bloodsworth, A., Eiserich, J. P., Coffey, M. J., McLoughlin, R. M., Giddings, J. C., Lewis, M. J., Haslam, R. J., Freeman, B. A., and O'Donnell, V. B. (2002) J. Biol. Chem. 277 5832–5840 [DOI] [PubMed] [Google Scholar]
- 37.Wanikiat, P., Woodward, D. F., and Armstrong, R. A. (1997) Br. J. Pharmacol. 122 1135–1145 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Trostchansky, A., Souza, J. M., Ferreira, A., Ferrari, M., Blanco, F., Trujillo, M., Castro, D., Cerecetto, H., Baker, P. R. S., O'Donnell, V. B., and Rubbo, H. (2007) Biochemistry 46 4645–4653 [DOI] [PubMed] [Google Scholar]
- 39.Ley, K. (1996) Cardiovasc. Res. 32 733–742 [PubMed] [Google Scholar]
- 40.Cui, T., Schopfer, F. J., Zhang, J., Chen, K., Ichikawa, T., Baker, P. R. S., Batthyany, C., Chacko, B. K., Feng, X., Patel, R. P., Agarwal, A., Freeman, B. A., and Chen, Y. E. (2006) J. Biol. Chem. 281 35686–35698 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Dulak, J., Deshane, J., Jozkowicz, A., and Agarwal, A. (2008) Circulation 117 231–241 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Wright, M. M., Schopfer, F. J., Baker, P. R. S., Vidyasagar, V., Powell, P., Chumley, P., Iles, K. E., Freeman, B. A., and Agarwal, A. (2006) Proc. Natl. Acad. Sci. U. S. A. 103 4299–4304 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Wright, M. W., Hock, T. D., Freeman, B. A., and Agarwal, A. (2007) Free Radic. Biol. Med. 43 S161 [Google Scholar]
- 44.Serhan, C. N., and Oliw, E. (2001) J. Clin. Investig. 107 1481–1489 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Smith, W. L., and Langenbach, R. (2001) J. Clin. Investig. 107 1491–1495 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Vermeulen, L., De Wilde, G., Notebaert, S., Vanden Berghe, W., and Haegeman, G. (2002) Biochem. Pharmacol. 64 963–970 [DOI] [PubMed] [Google Scholar]
- 47.Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., and Evans, R. M. (1995) Cell 83 803–812 [DOI] [PubMed] [Google Scholar]
- 48.Schopfer, F. J., Lin, Y., Baker, P. R., Cui, T., Garcia-Barrio, M., Zhang, J., Chen, K., Chen, Y. E., and Freeman, B. A. (2005) Proc. Natl. Acad. Sci. U. S. A. 102 2340–2345 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Crabb, J. W., O'Neil, J., Miyagi, M., West, K., and Hoff, H. F. (2002) Protein Sci. 11 831–840 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Uchida, K., and Stadtman, E. R. (1992) Proc. Natl. Acad. Sci. U. S. A. 89 4544–4548 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Ishii, T., Tatsuda, E., Kumazawa, S., Nakayama, T., and Uchida, K. (2003) Biochemistry 42 3474–3480 [DOI] [PubMed] [Google Scholar]
- 52.Uchida, K., and Stadtman, E. R. (1993) J. Biol. Chem. 268 6388–6393 [PubMed] [Google Scholar]
- 53.Levonen, A. L., Landar, A., Ramachandran, A., Ceaser, E. K., Dickinson, D. A., Zanoni, G., Morrow, J. D., and Darley-Usmar, V. M. (2004) Biochem. J. 378 373–382 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Kensler, T. W., Wakabayashi, N., and Biswal, S. (2007) Annu. Rev. Pharmacol. Toxicol. 47 89–116 [DOI] [PubMed] [Google Scholar]
- 55.Villacorta, L., Zhang, J., Garcia-Barrio, M. T., Chen, X. L., Freeman, B. A., Chen, Y. E., and Cui, T. (2007) Am. J. Physiol. 293 H770–H776 [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.

